Clinical Takeaway
In this phase 3 trial of 820 adults, the full-spectrum cannabis extract VER-01 was evaluated against placebo over 12 weeks for chronic low back pain, with longer-term follow-up extending to one year. The trial used a rigorous randomized, double-blind, placebo-controlled design across multiple centers, making it one of the more methodologically robust cannabis trials in this condition to date. Results from this study provide direct clinical evidence regarding whether a standardized full-spectrum Cannabis sativa extract can serve as a viable pharmacologic option for a condition where existing treatments frequently fall short.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for full-spectrum cannabis extract efficacy in chronic low back pain, a condition affecting over 500 million people globally with currently limited pharmacologic options. The large sample size (820 participants) and robust double-blind design with extended open-label follow-up offer the level of evidence needed to inform clinical decision-making and potentially establish cannabis-derived therapies as a safer alternative to conventional analgesics with known addiction and adverse effect profiles. If positive, these results could significantly expand the therapeutic armamentarium for CLBP management and provide a foundation for regulatory approval and clinical integration of standardized cannabis-based medicines.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of full-spectrum cannabis extract for chronic low back pain represents a meaningful addition to our limited pharmacologic toolkit, though several factors warrant careful interpretation before widespread adoption. The 12-week double-blind phase with 820 participants provides reasonably robust evidence, but the trial’s completion of the primary efficacy endpoint and safety profile require detailed examination of effect sizes, withdrawal rates, and adverse events that are not fully detailed in the abstract provided. Clinicians should consider that full-spectrum extracts contain variable cannabinoid and terpene profiles, potentially limiting reproducibility across patient populations and formulations, and the open-label extension phase may introduce bias regarding long-term tolerability. Additionally, we must account for baseline pain characteristics, concurrent medications including opioids, and whether outcomes measured functional improvement or merely pain reduction, as these distinctions significantly impact clinical utility. Given the existing safety concerns with current CLBP treatments and the pressing need for alternatives, this study warrants full review of its data, but practitioners should reserve judgment